This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clover Biopharmaceuticals Zukünftiges Wachstum

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.

n/a

Wachstumsrate der Gewinne

190.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	39.9%
Wachstumsrate der Einnahmen	47.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Jul 2023

Keine Aktualisierungen

Gewinn- und Umsatzwachstumsprognosen

SHSC:2197 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	2,341	N/A	N/A	N/A	1
12/31/2024	3,071	N/A	N/A	N/A	2
12/31/2023	2,571	N/A	N/A	N/A	2
6/30/2023	0	-665	N/A	N/A	N/A
3/31/2023	0	-1,559	N/A	N/A	N/A
12/31/2022	N/A	-2,452	-1,796	-1,691	N/A
9/30/2022	N/A	-4,145	-1,461	-1,356	N/A
6/30/2022	N/A	-5,838	-1,125	-1,021	N/A
3/31/2022	N/A	-5,927	-1,062	-969	N/A
12/31/2021	N/A	-6,016	-998	-918	N/A
12/31/2020	N/A	-913	363	477	N/A

Einkommen vs. Sparrate: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).

Ertrag vs. Markt: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market

Hohe Wachstumserträge: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).

Hohe Wachstumseinnahmen: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.

Künftige Eigenkapitalrendite: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time